C-FBJIMuna Therapeutics
small molecules, microglia, resilience
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-FBJI
C-FBJIC-FBJIsmall molecules, microglia, resilience
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Niels Plath, PhD, Muna Therapeutics, Copenhagen, Denmark, discusses recent developments in microglial and inflammatory biomarkers of Alzheimer’s disease (AD). There are currently some promising biomarker candidates, however it is critical for the field that these ideas are validated, not only in research models but also in human patients. These include imaging biomarkers of microglia reactivity, as well as cerebrospinal fluid and plasma levels of inflammatory proteins. An exciting recent development is the use of microvesicles that can be harvested from the blood but reflect centrally mediated immune activity. This interview took place at the Alzheimer’s Association International Conference (AAIC) 2022 in San Diego, CA.
Niels Plath, PhD, Muna Therapeutics, Copenhagen, Denmark, gives an insight to the latest Alzheimer’s disease (AD) research from Muna Therapeutics. Their current research is focused on targeting microglia in the context of neuroinflammation, via TREM2 agonism and Kv1.3 blockade which are both developing quickly through in vitro/in vivo validation platforms. At the same time, the team are utilizing transcriptomics data to identify novel target candidates. Several differentially expressed gene clusters have been identified in Alzheimer’s disease using this system, some of which map onto biological pathways that have already been associated with neurodegeneration. These findings provide novel entry points into highly relevant biological processes, which may point towards new drug targets. This interview took place at the Alzheimer’s Association International Conference (AAIC) 2022 in San Diego, CA.
Niels Plath, PhD, Muna Therapeutics, Copenhagen, Denmark, discusses the discovery and validation of novel therapeutics for neurodegenerative disorders, such as Alzheimer’s disease (AD). They are combining two platforms to achieve this, firstly, building on a target validation platform. This utilizes genetic information from genome wide association studies and builds on this by also looking at differential gene expression. Using methods such as spatial transcriptomics, they are analyzing human derived brain material in AD patients and comparing them to brain samples from subjects who show resilience to amyloid pathology. It is hoped that studying gene expression in these samples may identify genes that correlate with cellular vulnerability or neuroprotection. These findings are integrated with genetic and protein-protein interaction data to identify targets for novel therapeutics, which can pass through validation platforms. This starts with in vitro studies, then progressing to in vivo
Niels Plath, PhD, Muna Therapeutics, Copenhagen, Denmark, discusses the latest data implicating microglia in Alzheimer’s disease pathology. Recent genetic information from large-scale genome wide association studies has suggested microglia and microglia-expressed genes play a key role in neuroinflammation and neurodegeneration. Numerous studies identified genes significantly associated with Alzheimer's disease that are most strongly expressed in microglia, including CD33 and TREM2. Pathway analyses also emphasize the crucial role of the innate immune system and neuroinflammation in the pathogenesis of Alzheimer's disease. Additionally, transcriptomic studies in mouse models of Alzheimer’s disease have shed light on microglia diversity and the differing statuses in which they can exist. Ongoing work aims to define the functional correlates of distinct microglia states to elucidate the pathological roles of microglia and identify novel therapeutic targets. This interview took place at th
Dr. Muna Almarzouqi Law Firm – Silver Sponsor – 6th World Conference on International Arbitration Skip to content Facebook X YouTube LinkedIn Email WhatsApp Home About The Conference Agenda Agenda – Day One Agenda – Day Two Speakers Conference Hotel Partners Sponsors The Strategic Sponsor – QNB Gold Sponsors Al Zaman Law Firm Sultan Al-Abdulla & Partners Dr. Thani Bin Ali Al-Thani Law Firm Silver Sponsor Dr. Muna Almarzouqi Law Firm Supporting Organizations International Council for Commercial Arbitration Chartered Institute of Arbitrators (Ciarb) IFCAI Arbitration ICC Qatar A
Muna Al Marzouqi - SPE International Conference on Oilfield Chemistry (25OCC) Skip to main content Home About Message from the Program Chairperson Program Committee Industry Insights Attend Schedule of Events Travel & Accommodations Training Courses Technical Program Sponsor View the Sponsorship Gallery Exhibit Exhibit Space Contract Exhibitor Resources View the Floorplan SPE INTERNATIONAL CONFERENCE ON OILFIELD CHEMISTRY 09–10 April 2025 | Galveston Island Convention Center Home About Message from the Program Chairperson Program Committee Industry Insights Attend Schedule of Events
International Market Centers Names Jennifer Muna CEM as General Manager Tradeshows You need to enable JavaScript to run this app. ATL ATLANTA LV LAS VEGAS HP HIGH POINT NYC NEW YORK Exhibitor Directory Visit Discover Exhibit Source Year Round Las Vegas Market SEARCH Filters No Filters Selected Search Clear Search Clear the Search Form Useful Links Exhibitor Directory Registration Book Hotel About Market FAQs Floor Plans Market Plan Home Explore Market News & Trends DesignOn Blog September 20, 2018 International Market Centers Names Jennifer Muna, CEM, as General Manager, Tradeshows LAS VEGAS,
MUNA Convention - Registration Torchbearers of Islam: Spreading the Faith Globally MUNA 5 Agenda: Da'wah, Organization, Education, Social Service and Relationship Donate Toggle navigation Home Speakers Schedule Registration --> Registration Hotel Competition Bazaar Venue & Parking Debate Contact Us Registration Countdown to Convention MUNA Convention will take a pause in 2026. Please stay tuned for future updates. Attendee Registration --> Attendee Registration --> Booth Registration Individual $ / person Couple $ / couple (Children below the age of 5 is FREE) Family $ (Household/dependent
MUNA Convention by Muslim Ummah of North America Torchbearers of Islam: Spreading the Faith Globally MUNA 5 Agenda: Da'wah, Organization, Education, Social Service and Relationship Donate --> Sign In Sign Up --> Donate --> Toggle navigation Home Speakers Schedule Registration --> Registration Hotel Competition Bazaar Venue & Parking Debate Contact Us MUNA Convention will take a pause in 2026. Please stay tuned for future updates. MUNA Convention 2025 Torchbearers of Islam: Spreading the Faith Globally August 8th - 10th, 2025 Pennsylvania Convention Center, PA Donate MUNA Convention Registe
Abstract EGU26-15243 Vienna, Austria & Online | 3–8 May 2026 Vienna, Austria & Online | 3–8 May 2026 Vienna, Austria & Online | 3–8 May 2026 Programme Browse by sessions Personal programme Licence and copyright Recorded sessions For Conveners Convener introduction Financial support and waivers Convener guidelines and rules US and GDB guidelines ITS guidelines SC guidelines EOS guidelines Townhall meeting guidelines Chairperson guidelines How to use Gather For Authors Author introduction General information and format Financial support and waivers Presenter guidelines Licence and co
XBRL Viewer Please enable JavaScript to use the EDGAR Inline XBRL Viewer.
Thank you to Team Tenorio &... - McDonald's Guam & Saipan Facebook Log In McDonald's Guam & Saipan's Post McDonald's Guam & Saipan June 16 at 6:29 PM · Shared with Public Thank you to Team Tenorio & Muna-Barnes for coming in as a Gold Sponsor for McDonald's of Guam's 1st Annual Golf Tournament benefiting the Ronald McDonald House! To learn more about our upcoming Golf Tournament happening this Friday, June 19th, visit our website https://www.mcdonaldsguamandsaipan.com/2026golfclassic or call our Tamuning Office (671) 649- 9093/94 today. All rea
Dr. Muna Mahfoodh Al Manthari – World Cancer Conference Skip to content Event : World Cancer Congress, Summit & Exhibition 2025 Date : 03 to 06 November 2025 Venue : Oman Convention and Exhibition Centre (OCEC), Muscat, Oman Home About WCCSE25 Event About OCA Who Should Attend About Oman Our Partners Conference Programme Speaker Lineup Accreditation Conference Registration E-Poster Abstract Registration Exhibition & Sponsor Floor Plan Register as a Sponsor Register as an Exhibitor Venue Media & Resources Press Release Gallery Cancer in Oman Contact Us Home About WCCSE25 Eve
Peta-Gaye Dowdie. This... - LSU Track & Field Facebook Log In LSU Track & Field's Post LSU Track & Field Verified account February 3, 2025 · Shared with Public Peta-Gaye Dowdie. This #BlackHistoryMonth , we strive to celebrate some of the great trailblazers to walk on campus in Baton Rouge. Tied with Kimberlyn and Muna as the most-individually decorated SEC athlete in LSU history. All reactions: 207 25 comments 39 shares Like Comment Most relevant Author LSU Track & Field 2000 NCAA Outdoor Championships Dowdie wins the 200m title in 22.51 seconds, which she described as he
%PDF-1.7 %���� 15982 0 obj > endobj 16014 0 obj >/Filter/FlateDecode/ID[ ]/Index[15982 60]/Info 15981 0 R/Length 144/Prev 12292715/Root 15983 0 R/Size 16042/Type/XRef/W[1 3 1]>>stream h�bbd```b`��"�H�E �S ,�9 &��a�j"Y8��K0�,~ ̾&���d�"�jA�X9���,R V�D2��H�.0�D Z�H��@��x @�G� Ķg��s�1012��#�3 9� �a� endstream endobj startxref 0 %%EOF 16041 0 obj >stream h��X{pT���}$k ��s7Dؽ���d��!�lB�� O#��hxmF@|^D%(�h���A5�iǩ36Z ���P���V���i3S���N�w�.��vZ�?��ٹ{���{��w�=� � h~zu������M?>5�s̜ �y�^�`t�Q��� �-�����v癲�\Ar����X*��~ �S"��jQ��D dNRT� KC�T��˧ (��iA��QVr���|�� … v��@��s���N g`o!P��Ǿs�;��[1#P?�W����d endstream endobj 16007 0 obj >stream application/pdf ADI logo NEW Black and Red Adobe Illustrator CS6 (Macintosh) 2015-01-28T15:13:08Z 2015-01-28T15:13:08Z 2015-01-28T15:13:08Z proof:pdf uuid:65E6390686CF11DBA6E2D887CEACB407 xmp.did:F77F1174072068118083CEC9A41B8971 uuid:8ed03a84-8e29-2548-8fc9-9f69e7b7837d uuid:2c20c941-6e3e-1e41-ab2b-91e035755df4 xmp.did:c1f43850-cbbb-4f63-9534-78d029555a12 uuid:65E6390686CF11DBA6E2D887CEACB407 proo … dfed0c3ee xmp.did:7e459482-610b-4107-8cd4-85af83621fc6 proof:pdf converted from application/x-indesign to application/pdf Adobe InDesign CC 14.0 (Windows) / 2019-08-21T12:18:16+02:00 saved xmp.iid:7e459482-610b-4107-8cd4-85af83621fc6 2026-03-09T14:11:16Z Adobe Illustrator 30.2 (Macintosh) / uuid:b1d7e140-d607-9f41-843b-cd1ec6aeeb6d xmp.id:4d44c663-9096-5a43-8d2c-fe632dd73bce xmp.did:ecb948b1-c232-d44a-895a-6d7dfed0c3ee proof:pdf application/pdf Alzheimer France logo Adobe PDF … ��z��ܷ� ��Y3�:5��醉�&ދ!��I�I&�E��?z�� �K� endstream endobj 48 0 obj >stream application/pdf ADI logo NEW Black and Red Adobe Illustrator CS6 (Macintosh) 2015-01-28T15:13:08Z 2015-01-28T15:13:08Z 2015-01-28T15:13:08Z proof:pdf uuid:65E6390686CF11DBA6E2D887CEACB407 xmp.did:F77F1174072068118083CEC9A41B8971 uuid:8ed03a84-8e29-2548-8fc9-9f69e7b7837d uuid:2c20c941-6e3e-1e41-ab2b-91e035755df4 xmp.did:c1f43850-cbbb-4f63-9534-78d029555a12 uuid:65E6390686CF11DBA6E2D887CEACB407 proo … dfed0c3ee xmp.did:7e459482-610b-4107-8cd4-85af83621fc6 proof:pdf converted from application/x-indesign to application/pdf Adobe InDesign CC 14.0 (Windows) / 2019-08-21T12:18:16+02:00 saved xmp.iid:7e459482-610b-4107-8cd4-85af83621fc6 2026-03-09T14:11:16Z Adobe Illustrator 30.2 (Macintosh) / uuid:b1d7e140-d607-9f41-843b-cd1ec6aeeb6d xmp.id:4d44c66
XBRL Viewer Please enable JavaScript to use the EDGAR Inline XBRL Viewer.
%PDF-1.4 %���� 1 0 obj > endobj 3 0 obj > endobj 4 0 obj > stream x���Mo� ��|@�h�)���уs�ȩ>�I�"��堗�'ק��Y��u�u��c?;���P~��Z��� *�Y��S�d�P�]Lb�7���,�{�v�^�5�b�o����^���e ������7�����nL��o�W��kVF]���^�;������W�z}��߷���1��V�\�:;�_~zpr��j|t:I�pp�V���n�t�����}������w �g�k� ���rw�z��#1?k�h���wxg弨Cӽ ���L��j��V���V���_�����y��{���m���`�4��j���o�����b�w_�Y� ��مJ1��.n |vg�^����E7!� �\r����Ѿ|�u�m�A�fcE�h���������n�� �j�u��&����=F{��$�f����O�t鞴��tϛ�]/���N~�CL�������=���R��yyz�>N:���U�Y���p^w�Q��ȼ��=;|r=���� ,w�L����G[�N�+0,�b'�{�\�X!O�+0,u�W����n7��0JuG��
Lab News | MUNA Lab Mechanisms Underlying Neurocognitive Aging Lab Home Research Research Team Recent Publications Community Service Lab News Join Our Team Prospective PhD Applicants June 2026 Dr. Clark and our two grad students, Yemi and Abbey, had a great time spending a morning providing some great information about healthy aging and wellness at the St. James Brain Health Event. Thank you to all who attended and lectured for this fun and engaging presentation! May 2026 New Symposium Accepted for the 2026 Annual GSA Meeting in November! Dr. Clark and colleagues had their symposium titled, "N … Dr.Bush and Dr.Clark were awarded an American Heart Association Rapid Research Award Adam Bush (PI) and Alexandra Clark (Co-I) were awarded an American Heart Association Rapid Research Award for their project titled, "Visualizing Cerebral Microvascular Shunting in Cerebral Small Vessel Disease with MRI". Graduate student Yemi presents at CNS in Vancouver, CA Congrats to Dr. Clark and team for publishing a new paper in Neuropsychology! Dr. Clark and the new editorial team at … ogical Society of American meeting in Boston and was awarded a pre-dissertation award. Congratulations to Research Assistant, Ashley Chikkala, for winning the Liberal Arts Undergraduate Research Award for her project, "Neighborhood Disadvantages as a Mediator of Effects of Residential Segregation on Longitudinal Cognitive and Functional Outcomes among Black Older Adults". She will present her work at the International Neuropsychological Society Meeting in February 2 … blication. September 2025 Congrats to Dr. Clark and colleagues on their new NIH Grant, "StatWiseAI: An AI-Powered Educational Tool for Enhancing Methodological Rigor in Large-Scale Data Analysis You can read about the grant here: https://nursing.utexas.edu/news/bo-xie-secures-nih-grant-advance-ai-powered-research-training. The StatWiseAI project brings together an exceptional team of scholars across multiple disciplines and academic stages. August 2025 Dr. Clark and coll … gratulations to Abbey Hamlin on receiving the Pre-Dissertation Student Research Award from the Behavioral and Social Science Section, as well as a Travel Award to attend the upcoming Gerontological Society of America (GSA) conference. June 2025 Congratulations, Dr. Clark for being accepted to the NIA Butler William Scholars Program! Abbey's
News | Sanofi Ventures Skip to main content Home Team Approach Portfolio News SANOFI VENTURES © 2026 News Strategic Wins Sanofi and QuantHealth Team up to Advance AI-Powered Digital Twins and Clinical Trial Simulation Sanofi and QuantHealth Team up to Advance AI-Powered Digital Twins and Clinical Trial Simulation Close Private Israel and Boston https://quanthealth.ai Oct 01, 2025 — Sanofi and QuantHealth Team up to Advance AI-Powered Digital Twins and Clinical Trial Simulation View as PDF Sanofi and QuantHealth team up to advance AI-powered digital twins and clinical trial simulations to accel … 024. Following positive data from the Phase 3 trial, Fulcrum and Sanofi plan to submit marketing applications in the U.S., Europe, Japan, and other geographies. “Sanofi is a proven leader in developing therapeutics for rare neuromuscular diseases and is the ideal partner to maximize the opportunity and reach of losmapimod outside the U.S.,” said Alex C. Sapir, Fulcrum’s president and chief executive officer. “This deal aligns with our core strategy, allowing Fulcrum to remain … ors.com 917-680-5608 Evidation Extends Collaboration with Sanofi to Develop and Apply Real-World Evidence Evidation Extends Collaboration with Sanofi to Develop and Apply Real-World Evidence Close Private San Mateo, CA www.evidation.com Jan 10, 2022 — Evidation Extends Collaboration with Sanofi to Develop and Apply Real-World Evidence View as PDF Collaboration will focus on co-development of unique datasets to understand health in everyday life January 10, 2022 06:00 AM Easte … opportunities to orally deliver biologics, and nanobodies represent an exciting application of this platform,” said Samir Mitragotri, co-founder of i2O Therapeutics. i2O Therapeutics announced seed funding in April 2020, which was led by Sanofi Ventures, the corporate venture capital arm of Sanofi, and JDRF T1D Fund. The company also announced a strategic investment from Colorcon Ventures, the corporate venture capital fund of Colorcon, Inc. in December 2020. About i2O Therap … onducting regulatory-grade analytics, opening new doors for the development and application of medical treatments. “Today marks another important step in Sanofi’s digital transformation,” said Bernard Hamelin, MD, MSc, MBA, Global Head of Medical Evidence Generation, Sanofi. “By integrating these platforms, we strive to make faster, more informed
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Healthcare Catalysts: Upcoming milestones for paradigm breakers in antifungals, Alzheimer's, single cell tech, VR - ION AnalyticsION Analytics --> Healthcare Catalysts: Upcoming milestones for paradigm breakers in antifungals, Alzheimer's, single cell tech, VR - ION Analytics Header Script --> A service of Talk to us today Insights Services Services Mergermarket Debtwire Xtract Dealogic Infralogic Dealreporter Blackpeak Backstop KYC6 BarclayHedge Wealthmonitor Events About Us About Us Our editorial team Editorial Standards Board Contact Us News (Intelligence) Healthcare Catalysts: Up … ity story : F2G is exploring a Nasdaq listing and licensing deals as options to fund new modes of administration and for life cycle management purposes. Milestones and technology Phase IIb study: efficacy in invasive aspergillosis, coccidiodomycosis and other rare moulds, to be completed this year with data due in October. Phase III study initiated to compare Olorofim against Gilead Sciences ’ AmBisome , followed by the standard of care (SOC) in patients with invasive f … eakthrough Therapy designation from US FDA. It is planning on filing a new drug application (NDA) on the basis of US FDA Phase IIb data by the end of the year. The patient population is very narrow but often needs to be treated for months at a time, improving company’s revenue cycle. It is shifting focus to life cycle management, including inhaled and intravenous (IV) formulations. Comparable companies/deals Antifungal Fosmanogepix (APX001) developed by Amplyx Pharmaceu … s. (16/08/22) Muna Therapeutics explores options to fund Phase I clinical trials in early 2024 amid investor interest – CEO Danish Muna Therapeutics develops therapies to slow or stop neurodegenerative diseases including Alzheimer’s, Frontotemporal Dementia and Parkinson’s. Equity story : It is reviewing options to fund upcoming Phase I clinical trials for its first drug, including a Series B funding round, an IPO or a partn … lobal M&A trends and risks 2026 Report Premium 22nd June 2026 Shein aims to submit confidential Hong Kong lPO filing in 3Q26 22nd June 2026 Ottawa push draws Canadian pensions back home News (Intelligence) Contact Us Services Mergermarket Debtwire Xtract Dealogic Infralogic Dealreporter Blackpeak Backstop KYC6 BarclayHedge Wealthmonitor More
Manuela Polydoro - BIO International Convention 2026 Save the date: June 7-10, 2027 BIO is back in Philadelphia in 2027! Save the date: June 7-10, 2027 BIO is back in Philadelphia in 2027! June 7-10 | Philadelphia Event Info Event Overview About BIO International Convention Future dates Attendee Policies Schedule at a Glance FAQs International Visitors Why Attend Visa Invitation Letter Request Tips for International Visitors Share On Social Media For Press Media Resource Center Media Registration Engaging with the Media Request Media List Press Releases Stay in Touch Contact Us Join our mailin … ific Progress AI Implementation Biomanufacturing Academia Company Presentations Apply for a Company Presentation 2026 Presenting Companies Curated Programs AI Summit BIO Storytelling Stage BioProcess Theater Global Innovation Hubs Professional Development Courses Start-Up Stadium Student Program BIO Partnering™ BIO Partnering™ at BIO 2026 BIO Partnering™ Overview Pre-Event Webinars Partnering Resources LOG IN TO BIO PARTNERING Participating Companies All Partnering Companies … Amgen Genentech Boehringer Ingelheim Lilly Novo Nordisk Sanofi Academic Campus Apply for Academic Campus Exhibition Directory and Map Event Directory Exhibitor List Exhibitor In-Booth Events Event Map Exhibition Hours Exhibition Reception BIO Booths BIO Business Solutions® Pavilion BIO Member Lounge Networking BIO Receptions Other Events Social Spotlight Events Affiliate Events Application Special Experiences 5K and 1 Mile Course BIO Gives Back Headshot Lounge Matchday Loung
EX-4.28 9 g083881_ex4-28.htm EXHIBIT 4.28 Exhibit 4.28 STOCK ISSUANCE AGREEMENT This STOCK ISSUANCE AGREEMENT (this “ Agreement ”) is made as of December 23, 2023 (the “ Effective Date ”) between Chromocell Therapeutics Corporation, a Delaware corporation (“ Chromocell ”) and Benuvia Operations, LLC, a Delaware limited liability company (“ Benuvia ”). Chromocell and Benuvia are collectively referred to herein as the “ Parties .” RECITALS WHEREAS, Subject to the terms and conditions set forth in this … ng, Chromocell hereby agrees that the provisions of this Section D(i) shall not apply to the following: (a) the purchase by Benuvia and/or its affiliates after the date hereof (and not pursuant to this Agreement) of up to an aggregate number of shares of Common Stock that does not exceed 10 % of the number of shares of Common Stock then issued and outstanding; (b) the exercise by Benuvia and/or its affiliates, if applicable, of any voting rights available to Com
%PDF-1.7 %���� 5 0 obj > stream x��ݽ�i�&����8�=���p0h�p0����QΔ��p���Q��6FI�R9oK�g��4M��>)�T����|�Y�Yq]����D��x⎈�������� �������_""R&���������� ������˯���H������oR� ���_���� ��E���BPD�d�L�""%�`�)� ���H�(�(EDJF!�D!("R2 A& A��Q0Q����B��BPD�d�L�""%�`�)� ���H�(�(EDJF!�D!("R2 A& A��Q0Q����B��BPD�d�L�""%�`�)� ���H�(�(EDJF!�D!("R2 A& A��Q0Q����B��BPD�d�L�""%�`�)� ���H�(�(EDJF!�D!("R2 A& A��Q0Q����B��BPD�d�L�""%�`�)� ���H�(�(EDJF!�D!("R2 A& A��Q0Q����B��BPD�d�L�""%�`�)� ���H�(�(EDJF!
MUNA | Pennsylvania Convention Center Skip to content Accessibility Buy Tickets Search Pennsylvania Convention Center Search Meeting Professionals - Pennsylvania Convention Center Meet Our Sales Team Meeting Planner Tools Plan of Operations Contractor Services Documents Site Visits Destination Planning Guide Services Floor Plans Exhibit Halls Meeting Spaces By the Numbers Safety & Emergency Procedures FAQs Testimonials Limited-Time Incentives Subscribe to the PCC Quarterly Newsletter Exhibitors - Pennsylvania Convention Center Exhibitor FAQs and Exhibitor Work Rules Amenities FedEx Business Ce
376627159-1-29-2026-20-CC-GGOZ-DQT3S8-20260129172954 <meta name="robots" content="noindex"> Department of SOCIAL SERVICES Community Care Licensing FACILITY EVALUATION REPORT Facility Number: 376627159 Report Date: 01/16/2026 Date Signed: 01/29/2026 05:30:20 PM Document Has Been Signed on 01/29/2026 05:30 PM - It Cannot Be Edited STATE OF CALIFORNIA - HEALTH AND HUMAN SERVICES AGENCY FACILITY EVALUATION REPORT CALIFORNIA DEPARTMENT OF SOCIAL SERVICES COMMUNITY CARE LICENSING DIVISION CCLD Regional Office , 7575 METROPOLITAN DR., STE 110 SAN DIEGO , CA 92108 FACILITY NA … any disagreement in this report with the licensing agency concerning the proper application of licensing requirements. The applicant/ licensee may request a formal review by the licensing agency to amend or dismiss the notice of deficiency and/ or civil penalty. Requests for review shall be made in writing within 15 business days of receipt of a deficiency notification or civil penalty assessment. Licensing deficiencies may be appealed pursuant to the procedures in the LIC 90
EQT Life Sciences portfolio company Muna Therapeutics and GSK today announced a new partnership to identify and develop novel treatments for Alzheimer’s disease. This collaboration is centered… | Edwin van den Broek CFP® LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choic … GENF) (OTCQB:GENFF) has announced the publication of its second European patent application, “SIRT6 Variant for NASH”, in the European Patent Bulletin. This milestone strengthens Genflow’s expanding #IP portfolio and reinforces its leadership in longevity and metabolic disease innovation. With both of its key #SIRT6 applications now provisionally protected in Europe, #Genflow continues to advance its platform targeting age-related and metabolic disorders, including #NASH . Re … Broek CFP® 9y LSP announces $280 million final closing of life sciences venture fund. Edwin van den Broek CFP® 10y Explore content categories Career Productivity Finance Soft Skills & Emotional Intelligence Project Management Education Technology Leadership Ecommerce User Experience Recruitment & HR Customer Experience Real Estate Marketing Sales Retail & Merchandising Science Supply Chain Management Future Of Work Consulting Writing Economics Artificial Intellige
News Details About Us Our Team Board of Directors Our Scientific Founders Scientific Advisory Board Medicinal Chemistry Advisory Board Our Investors Our Science Careers News Contact January 8, 2026 Muna Therapeutics Awarded $1 Million Alzheimer's Association Grant to Advance Clinical Development of Novel Oral TREM2 Agonist MNA-001 for Alzheimer’s Funds to support ongoing Phase 1 trial of MNA-001 and validation of translational biomarkers for TREM2 function in Alzheimer’s Work will inform Phase 2 trials assessing the potential of MNA-001 to slow pathology progression and functional decline Vali … egenerative diseases, today announced it has been awarded a $1 million research grant from the Alzheimer’s Association to support its ongoing Phase 1 trial of MNA-001 —a novel potent, selective and orally administered small molecule, in healthy young and elderly subjects—and its work to identify and validate translational biomarkers of the function and activation of triggering receptor expressed on myeloid cells 2 (TREM2) in the context of Alzheimer’s disease. These efforts w … euroinflammation. "We are grateful to the Alzheimer’s Association for this award, which will accelerate clinical evaluation of MNA-001 and validation of critical biomarkers of TREM2 agonism," said Rita Balice-Gordon, Ph.D., Chief Executive Officer of Muna Therapeutics. "The grant supports our strategy to shift the treatment paradigm from clearing pathology to bolstering the brain's innate protective mechanisms. By recalibrating microglial activity, we aim … a potentially transformative approach to treating early Alzheimer’s." This award underscores Muna’s growing momentum and its leadership in the discovery of resilience-based therapeutics to slow or stop devastating diseases like Alzheimer’s to improve the quality of life for patients and their loved ones. About Muna Therapeutics Muna Therapeutics is pioneering a new era of drug discovery for neurodegenerative diseases by focusing on enhancing resilience to the effects of … by funding support from top-tier organizations. This includes the new research grant from the Alzheimer’s Association, a strategic alliance with GSK, prior funding from The Michael J. Fox Foundation, and funding from blue-chip biopharma investors, underscoring strong confidence in our resilience-based approach. Q: How will the Alzheimer’s Associ
%PDF-1.4 %���� 1 0 obj > endobj 3 0 obj > endobj 5 0 obj > stream x��ZKo7��W�@i� �C����zh*�� M Mк)П�Y��K-w"��^ �@`�h��o>����_���{W�(���6l�Х쉸Cr L�;��.� a@������>��ę}����Lj)CW�"��E�;Q�~�}� �yy�ܼ���� p�z �:߁��|���_ׄ�.S���Ӣ%�� >�� ��"��onvA�q!�K����qH4�9&Qk��?mn�G����n�qLB���/� ��C�Q�A�L^É�F24x��sd�L= ��Ϣ��[�O�T���Ly�1���D�Mq�2OF�ag�a�i�;�cI;��xrn� �pG ��/��`�¡V E$L.��϶d �@,��%�F��j���J V;7�5�hv�,�z��Xg��o;�N� ��~`,�?���20�� ȕBL� ��$= Y��('����}���پ���� �����v;�Z㻻���a"�������#0�2P��Ȥ� R�@��:�O7P�DP�cE�z���� \$��A�W`�-��� u�N���PC�q'� �� > stream x
#aaic2025 #neurodegeneration #alzheimers | Muna Therapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy … was honored with the Alzheimer's Association® Khalid Iqbal Lifetime Achievement Award in Alzheimer’s Disease Research at the #AAIC2025 meeting! Dr. De Strooper's pioneering work, including his focus on human-relevant models to understand causal genes driving #neurodegeneration , underpins Muna's innovative approach to #Alzheimers research. His impactful research over 30+ years has provided fundamentally new insights into Alzheimer’s disease pathophysiology, and his deep commi … 1mo Report this comment Impressive work! Well done ! Like Reply 1 Reaction Grant Smillie 11mo Report this comment A great achievement. Congrats Bart Like Reply 1 Reaction Marcus Mikeli Olsen 11mo Report this comment Congrats 🙂 Like Reply 1 Reaction Teresa Carroll 11mo Report this comment Congrats! 🎉 Like Reply 1 Reaction See more comments To view or add a comment, sign in 9,045 followers View Profile Follow Explore content categories Career Productivity
Partnering with GSK | GSK Skip to content Skip to search Behind the Science magazine Company Company Purpose, strategy and culture GSK at a glance History and heritage Board of Directors and Executive Committee Board information Governance Governance Committees Shareholders Sarbanes-Oxley Act 2002 Compliance Policy positions Codes, standards and reports Innovation Innovation Our leading scientists Our leading scientists Dr Tony Wood Dr Sabine Luik Dr Hesham Ahmed Abdullah Dr Kaivan Khavandi Dr Christopher Austin Research and development approach Pipeline Therapeutic areas Therapeutic areas Res … opment and Supply (MDS) Genomic sciences Technology Early careers Early careers Application process Apprentice programmes Internships and placements Graduate programme Graduate programme Business operations Engineering Manufacturing & supply Commercial Research & development Digital & tech Manufacturing sciences & technology Post graduate opportunities Frequently asked questions Veterans Our global and regional hubs How we hire How we hire Fraudulent internet … and bring life-saving treatments to patients more efficiently. Partner with us Submit ideas or contact us for collaboration opportunities: Academics, Biotechs and TechBios Medicines Vaccines Supported studies Some of our recent collaborations By working with partners, we can achieve more and ensure faster innovation to address disease areas of high unmet need for as many people as possible. Our collaborations with our partners underscore our commitment to finding novel treat
Muna AbuSulayman - Women’s Peace and Humanitarian Fund Skip Navigation --> --> Menu Close About Annual Report 2024 Our Mission We are an innovative partnership empowering local women to be a force for crisis response and lasting peace. Our History Our Global Steering Committee Our Donors Climate Security Food Security Financial Information Global Impact News Countries Active Countries Learn about the countries currently receiving WPHF support. Reserve List Countries See the full list of countries eligible for WPHF support. Funding Regular Funding Cycle Discover new funding opportunities for ci … e and Security and Humanitarian Action (trading as Women’s Peace & Humanitarian Fund) English This site uses cookies to provide you with a quality user experience. By continuing to use our site, you accept our use of cookies. Ok Back to Top Share Video
GSK's third new pact of the week focuses on Alzheimer's with startup Muna Therapeutics | Simon Glerup LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in,
Simon Glerup - BioLeader Interview - PIR International Skip to content Search for: Home About Us Executive Search Board Appointments Interims & Fractionals BioLeaders Remuneration & Diversity Studies News Contact Us Search for: NEWS Simon Glerup – BioLeader Interview Alex Hope 2026-05-13T07:59:42+00:00 Chief Scientific Officer and Co-founder of Draupnir Bio, Co-founder of Teitur Trophics and Muna Therapeutics (September 2023) Simon Glerup is CSO, co-founder and board member of Draupnir Bio , co-founder of Teitur Trophics , and co-founder of Muna Therapeutics . He is also associ
Scientific Page About Us Our Team Board of Directors Our Scientific Founders Scientific Advisory Board Medicinal Chemistry Advisory Board Our Investors Our Science Careers News Contact Scientific Advisory Board Bart De Strooper, MD, PhD Professor, Vlaams Instituut voor Biotechnologie (VIB), Belgium and the Katholieke Universiteit Leuven (KU Leuven) Director, United Kingdom Dementia Research Institute, University College London Scientific founder, Muna Therapeutics and Chair of the Scientific Advisory Board Simon Glerup, PhD Professor of Biomedicine, Aarhus University, Denmark Chief Scientific
Rita Balice-Gordon · Muna Therapeutics ApS | Paqle Bli bruker Logg inn Søk i Paqle Søk i Paqle Min side IT-systemer Rita Balice-Gordon Muna Therapeutics ApS Følg Følg Rita Balice-Gordon Muna Therapeutics ApS 1 Roller Følg Følg Balance Roller Muna Therapeutics ApS DKK 311 mio Adm. direktør, bestyrelsesmedlem Relasjoner Luc Madeleine Albert Dochez Muna Therapeutics ApS 2025 - nå Camilla Petrycer Hansen HIGHLINE ApS 2025 - nå Eileen Elizabeth McGuire Muna Therapeutics ApS 2022 - nå Donald William Nicholson Muna Therapeutics ApS 2021 - nå Cillian King Muna Therapeutics ApS 2021 - nå Se alle 15 Kor
Rita Balice-Gordon, Ph.D. - Capsida Biotherapeutics About Overview Leadership Team Board of Directors Investors History Contact Innovation Capsida Approach CNS Ophthalmology Capsid Engineering and Preclinical Manufacturing Operations News Press Releases Community Updates Publications Careers Culture & Benefits Current Opportunities Rita Balice-Gordon, Ph.D. Rita Balice-Gordon is the Chief Executive Officer of Muna Therapeutics, a new biotech company focused on developing novel therapeutics for patients with neurodegenerative diseases, which recently raised $73M in a Series A funding round
Niels Plath, Muna Tx’s CSO, will be speaking about our work on next generation therapeutics for neurodegenerative diseases at Bio-Neuroscience in Amsterdam. | Muna Therapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Rej
Muna Therapeutics ApS | Roller og ejerstruktur | eStatistik Nyheder 17. november 2023 Dansk jobrekord med ”aber dabei” 29. juni 2023 TEMA om it-sektoren: Økonomisk udvikling 29. juni 2023 TEMA om it-sektoren: Virksomheder og iværksætteri 29. juni 2023 TEMA om it-sektoren: It-arbejdsmarked og uddannelsesniveau - meget mere end techvirksomheder 29. juni 2023 TEMA om it-sektoren: Beskæftigelsen sætter rekord! Værktøjer find_in_page Find virksomheder Søg efter virksomheder og få adgang til virksomheds- og regnskabsdata hentet direkte fra CVR-registeret. Søgningen indeholde … ksomheden siden 08. juli, 2021. Virksomheden er udenlandsk. 0.05/1 LSP Dementia Fund Coöperatieve UA Legal ejer med 5 - 9,99% af virksomheden siden 08. juli, 2021. Virksomheden er udenlandsk. 0.15/1 Sofinnova Capital IX Legal ejer med 15 - 19,99% af virksomheden siden 30. juni, 2022. Virksomheden er udenlandsk. dashboard Virksomhedens datterselskaber Muna Therapeutics ApS har ingen datterselskaber. hourglass_empty Historisk udvikling af rollerne hourglass_full 27. oktobe … den. Droia GD SCSp tiltrådte som ejer 15 - 19,99% af virksomheden. LSP Dementia Fund Coöperatieve UA tiltrådte som ejer 5 - 9,99% af virksomheden. Sofinnova Capital IX tiltrådte som ejer 10 - 14,99% af virksomheden. hourglass_full 06. juli, 2021 Axxam S.p.A. tiltrådte som ejer 25 - 33,33% af virksomheden. Rita Balice-Gordon tiltrådte som ejer 25 - 33,33% af virksomheden. hourglass_full 19. marts, 2021 Novo Holdings A/S tiltrådte som ejer 33,34 - 49,99% af virksomheden. Axxam
Joachim Vilstrup | Muna Therapeutics | HealthTech Alpha Personal Information at Experience Galengrowth Present - Present Education Galengrowth Univesity Galengrowth Degree About About Contact Us Knowledge Center Legal Terms & Conditions Privacy Connect With Us Copyright 2026 | Galen Growth | All Right Reserved
Biotech company with its roots in Aarhus raises DKK 450 million from international foundations Aarhus University logo Find Dansk For students For PhDs For employees Local study portals Molecular Biology Molecular Medicine Local PhD portal Molecular Biology and Genetics Pages for all PhD students phd.au.dk Local staff information Department of Molecular Biology and Genetics - Staff portal Pages for staff members at AU medarbejdere.au.dk/en Department of Molecular Biology and Genetics Research Research areas Group leaders Research centres Peer-reviewed articles Responsible conduct of research an … ssociate Professor Sune Skeldal. Only two-and-a-half years ago, he submitted an application for DKK 500,000 to the Novo Nordisk Foundation from the Department of Biomedicine – today the company has received almost half a billion kroner from large international foundations. "It's fantastic to see how fast and explosive our growth has been. The new investors rubber stamp the work we’ve being doing at Aarhus University in recent years. There are people who really believe we can … lgian Bart De Strooper received the Lundbeck Foundation's prestigious The Brain Prize, the world's biggest brain research prize, for his highly specialised studies of Alzheimer's and other forms of dementia. The ownership of Muna Therapeutics consists of, among others, the five founders from Aarhus University: Associate Professor Simon Glerup , Assistant Professor Camilla Gustafsen , Postdoc Joachim Vilstrup , Associate Professor Peder Madse … candidates. The investors are: Novo Holdings, Sofinnova Partners, LSP Dementia Fund, Droia Ventures, Polaris Partners, Polaris Innovation Fund, Sanofi Ventures and V-Bio Ventures. Muna Therapeutics is headed by CEO Rita Balice-Gordon, COO Anders Hinsby and Chief Development Officer Jakob Busch-Petersen. Morten Graugaard Døssing is chair of the board - see the entire board here: Board of Directors – Muna Therapeutics Read more at https://munatherapeutics.com/ Cont
Joachim Vilstrup - Head, Protein Chemistry & Structural Biology at Muna Therapeutics | The Org Platform Enrich Pricing Log in Sign up Muna Therapeutics Joachim Vilstrup Unverified Joachim Vilstrup Head, Protein Chemistry & Structural Biology Contact Joachim has more than 7 years of experience in protein chemistry and early-stage drug discovery in academia and biotech focused on cardiovascular and neurodegenerative diseases. Joachim is a scientific co-founder of Muna and holds a Ph.D. in protein chemistry and structural biology. Prior to joining Muna, he led protein chemistry, structu
Rita Balice-Gordon - paasp network Home Services Incubator Network News Resources Contact us Newsletter Search Site Home Team Rita Balice-Gordon Rita Balice-Gordon Rita Balice-Gordon, Ph.D., is the CEO of Muna Therapeutics, a newly formed Neurology focused biotech company working on developing novel therapeutics for neurodegenerative diseases. She is working with Anders Hinsby, Jakob Busch-Petersen, Joachim Vilstrup, Simon Glerup Pedersen and the team at Novo Ventures to transform cutting-edge science into impactful therapeutics for CNS diseases. Dr. Balice_Gordon was the Global Head, Rare and
Biotech company with its roots in Aarhus raises DKK 450 million from international foundations Aarhus University logo Find For students For PhDs For employees Local study portals Biomedical engineering Medicine Medicinal chemistry Molecular medicine Odontology Brightspace Local PhD portal Graduate Programme: Biomedicine Graduate School of Health Pages for all PhD students phd.au.dk Local staff information Biomedicine - Staff Portal Common pages for staff members at AU medarbejdere.au.dk/en/ Department of Biomedicine About us Management Vacant positions Innovation Laboratory Animal Facility New … ssociate Professor Sune Skeldal. Only two-and-a-half years ago, he submitted an application for DKK 500,000 to the Novo Nordisk Foundation from the Department of Biomedicine – today the company has received almost half a billion kroner from large international foundations. "It's fantastic to see how fast and explosive our growth has been. The new investors rubber stamp the work we’ve being doing at Aarhus University in recent years. There are people who really believe we can … lgian Bart De Strooper received the Lundbeck Foundation's prestigious The Brain Prize, the world's biggest brain research prize, for his highly specialised studies of Alzheimer's and other forms of dementia. The ownership of Muna Therapeutics consists of, among others, the five founders from Aarhus University: Associate Professor Simon Glerup , Assistant Professor Camilla Gustafsen , Postdoc Joachim Vilstrup , Associate Professor Peder Madsen and Associate Professor Sune … candidates. The investors are: Novo Holdings, Sofinnova Partners, LSP Dementia Fund, Droia Ventures, Polaris Partners, Polaris Innovation Fund, Sanofi Ventures and V-Bio Ventures. Muna Therapeutics is headed by CEO Rita Balice-Gordon, COO Anders Hinsby and Chief Development Officer Jakob Busch-Petersen. Morten Graugaard Døssing is chair of the board - see the entire board here: Board of Directors – Muna Therapeutics Read more at https://munatherapeutics.com/ Contact: … gree Programmes Bachelor Master Engineering PhD Shortcuts Core-facilities Nobel Prize winner from Biomedicine © — Cookies at au.dk Privacy Policy Accessibility Statement 9607 / i34
Anders Hinsby Muna Therapeutics ApS [LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal Zum Inhalt News People Events Deals Organisations Newsletter About us Contact Top News Merck KGaA to Acquire Bio-Techne for $11.3b (€9.9b) Merck Announces Healthcare Leadership Changes RQ Biotechnology Closes $115m (£85.5m) Series A Financing Tecan Integrates Nvidia’s Agentic AI into Lab Platform Nvidia Announces BioNeMo Agent Toolkit at BIO 2026 Merck Partners with Versant Ventures to Launch Saturnus Bio Coulter Partners Places Vincent Metzler as CEO of Cellcolabs Europe Unveils a Record … rapeutics Raises $5m Investment Led by Daphni Kos Biotechnology Partners: First Fund Reaches $123m Caszyme: WiFIX Consortium Awarded €1m Eurostars Grant AMD, Dell & Univ Cambridge Launch UK AI Innovation Lab GSK to Acquire Nuvalent for $10.6b in Cash Merck Appoints Two Life Sciences Leadership Team Members AMD Commits up to £2b to Accelerate AI in UK » More News! » Submit your News! Upcoming Events EUROMAR 2026 Gothenburg (Göteborg) Gitex AI Europe 2026 Berlin Bay … 2027) bio:cap Investival 2027 Berlin (BioCap 2027) » More Events! » Submit your Event! Management Appointments Endress+Hauser Appoints Christian Mäder as Future CFO Orlando Oliveira Succeeds Dario Eklund as CEO of Santhera Merck Healthcare Appoints Head of Global Commercial Strategy Clara Sattler de Sousa e Brito Joins Merck (DE) from Philips Evotec Nominates Dieter Weinand as Supervisory Board Chair Santhera Appoints Marc Clausse as Chief Commercial Officer Coult … ion Appoints Fred Chereau as Chief Executive Officer » More News! » Submit your News! Financings & Acquisitions Merck KGaA to Acquire Bio-Techne for $11.3b (€9.9b) RQ Biotechnology Closes $115m (£85.5m) Series A Financing GSK to Acquire Nuvalent for $10.6b in Cash Ona Therapeutics Raises $86.6mSeries B to Advance ADCs Olix Pharma Secures KRW110b Investment from BOLD and Weiss T-Curx GmbH Acquires Pantherna Therapeutics GmbH Genovis Acquires KPL ApS for DKK30.5m Up … henoVista Biosciences to Expand in US Lauxera Capital Partners Closes Growth II Fund at €520m » More News! » Submit your News! Collaborations & Licensing Roche and Nurix: up to $2.3b Agreement for BTK Degrader Fusix Biotech & Recipharm Advance Oncolytic Virus Platform Lundbeck & Cradle Partner for AI-based Brain Disorder R&D Bonito Bi
Alzheimer's research start-up attracts €60 million | Mission Lucidity Skip to main navigation Mission Lucidity - decoding brain disease Main navigation Home About Team Research News Connect Menu Alzheimer's research start-up attracts €60 million A European start-up, co-led by Professor Bart De Strooper, launched today with an initial capital of €60 million. The company aims to advance small molecule therapeutics for neurodegenerative diseases. The new start-up, Muna Therapeutics, is pioneering the development of first-in-class small molecule therapeutics for neurodegenerative disease
Scientific Founders Page About Us Our Team Board of Directors Our Scientific Founders Scientific Advisory Board Medicinal Chemistry Advisory Board Our Investors Our Science Careers News Contact Our Scientific Founders Bart De Strooper, MD, PhD Bart is an internationally renowned physician scientist at Vlaams Instituut voor Biotechnologie (VIB), Belgium and the Katholieke Universiteit Leuven (KU Leuven) and the Director of the United Kingdom Dementia Research Institute at University College London. He and his team have made groundbreaking contributions to understanding and treating Alzheimer’s
Muna Therapeutics - Drug Discovery World (DDW) Drug Discovery World (DDW) About Us | Subscribe Free | Media Info | Contact Us | Log In News Exclusive Content Features Opinion Market Reports Trends & Analysis Start-up Zone DDW eBooks Business & Investment Regulatory Events DDII Events Series Other Events Webinars Resources Magazine Digital Issues Archive Multimedia Videos Podcasts Topic filter: Cancer Research Immunology / Virology & Vaccines Advanced Therapies Neuroscience Multiomics Artificial Intelligence Automation & Robotics Therapeutic Antibodies Microbiome Drug Discovery Cell Science
Medicinal Chemistry Page About Us Our Team Board of Directors Our Scientific Founders Scientific Advisory Board Medicinal Chemistry Advisory Board Our Investors Our Science Careers News Contact Medical Chemistry Advisory Board Liesbeth DeLange, PhD Principal Investigator, Predictive Pharmacology, Division of Systems Biomedicine and Pharmacology, Leiden Academic Center for Drug Research, Leiden University, The Netherlands Malcolm McCoss, PhD, FRSC Visiting Professor of Chemistry for Medicine, University of Oxford, Oxford, UK and Founder, Bohicket Pharma Consulting, LLC David Witty, PhD Vice Pre
Careers | Muna Therapeutics About Us Our Team Board of Directors Our Scientific Founders Scientific Advisory Board Medicinal Chemistry Advisory Board Our Investors Our Science Careers News Contact Careers Our Mission We transform groundbreaking science into life-changing medicines for patients with neurodegenerative disorders. Our Values Innovation We believe science is driven by curiosity, and that great science leads to innovation that benefits humanity. Care We think about our patients in every decision we make. Integrity We work with integrity, flexibility and perseverance. Passion We cons
Careers | Muna Therapeutics About Us Our Team Board of Directors Our Scientific Founders Scientific Advisory Board Medicinal Chemistry Advisory Board Our Investors Our Science Careers News Contact Careers Our Mission We transform groundbreaking science into life-changing medicines for patients with neurodegenerative disorders. Our Values Innovation We believe science is driven by curiosity, and that great science leads to innovation that benefits humanity. Care We think about our patients in every decision we make. Integrity We work with integrity, flexibility and perseverance. Passion We cons
Muna Therapeutics ApS som arbejdsplads | Jobindex 31.500 job i dag For jobsøgere For arbejdsgivere DA EN Log ind Opret profil Jobsøgning Søg job Vælg mellem flere søgekriterier Din side Skab overblik over din jobsøgning Jobagent Få nye job direkte i din indbakke CV Opret dit CV og bliv headhuntet QuickApply-profil Søg jobbet nemt fra mobilen Jobannoncearkiv Find inspiration i udløbne jobopslag Få en jobvejleder Bliv afklaret i din jobsøgning Jobs For Ukraine Hjælper ukrainske flygtninge med at få job Arbejdspladser Se virksomhedsprofiler Få viden om din næste arbejdsplads Evaluér arbejdsplads
Muna Therapeutics - Research and Development | The Org Platform Enrich Pricing Log in Sign up Muna Therapeutics Teams Research and Development Unverified Research and Development 13 people · 0 jobs The Research and Development team at Muna Therapeutics focuses on discovering and advancing therapies targeting neurodegenerative diseases such as Alzheimer's and Parkinson's. This multidisciplinary team conducts cutting-edge laboratory research, bioinformatics analysis, and innovative scientific exploration to identify and develop potential treatment options. They work collaboratively t
Proud of the Muna team, and looking forward to a productive and rewarding 2024! | Rita Balice-Gordon LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree
Is Muna a Male or Female Name? genderize.io genderize.io agify.io nationalize.io Documentation Spreadsheets Resources Our Data Case Studies FAQ Pricing Log in Sign up Documentation Spreadsheets Resources Our Data Case Studies FAQ Pricing Log in Register We can't find the internet Attempting to reconnect Something went wrong! Hang in there while we get back on track Home Popular Names Muna Is Muna a Male or Female Name? Muna is predominantly a female name Gender Distribution Historic Popularity Popular Countries Age Distribution Gender Distribution The gender distribution of people named Mu
Muna Awwadova | Partner | Kingsley Gate Skip to content What We Do Close What We Do Open What We Do Executive Search Professional Search Our Expertise Close Our Expertise Open Our Expertise By Sector Close By Sector Open By Sector Financial Services Asset Management Digital Assets Equities Fixed Income & Foreign Exchange Investment Banking & Private Markets Hedge Funds Commodities Systematic Markets Technology Corporate Functions Asset Management Digital Assets Equities Fixed Income & Foreign Exchange Investment Banking & Private Markets Hedge Funds Commodities Systematic M … th Me Email Muna Awwadová Your Name Your Email Address Please Post Your Message Submit Kingsley Gate Partners, LLC needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, please review our Privacy Policy.
%PDF-1.4 %���� 6 0 obj > endobj xref 6 36 0000000016 00000 n 0000001266 00000 n 0000001326 00000 n 0000001661 00000 n 0000001788 00000 n 0000001922 00000 n 0000002045 00000 n 0000002081 00000 n 0000002509 00000 n 0000002997 00000 n 0000003652 00000 n 0000004217 00000 n 0000004783 00000 n 0000005493 00000 n 0000006074 00000 n 0000006204 00000 n 0000006859 00000 n 0000006938 00000 n 0000007588 00000 n 0000008240 00000 n 0000019430 00000 n 0000019645 00000 n 0000020233 00000 n 0000038291 00000 n 0000038498 00000 n 0000039334 00000 n 0000046810 00000 n 0000047035 00000 n 0000047376 00000 n 0000047 … tream endobj 3 0 obj > endobj 4 0 obj >stream Skia/PDF m93 Google Docs Renderer application/pdf Muna Tree Classroom Supply List (2021-2022) 2021-07-12T12:42:26+03:00 2021-07-12T12:42:26+03:00 2021-07-12T12:42:26+03:00 uuid:3a84af5f-2669-4764-98f9-8af97789a4ec uuid:fa54581c-10f4-4066-894f-7c5e0bd5ea85 endstream endobj 5 0 obj > endobj xref 0 6 0000000000 65535 f 0000755046 00000 n 0000755288 00000 n 0000757163 00000 n 0000757220 00000 n 0000760593 00000 n trailer ]>> startxref
GSK builds neuro, cancer pipeline with trio of deals | pharmaphorum Skip to main content Friday 26 June 2026 BlueSky linkedin youtube header links Get Newsletters Media Kit Pharmaphorum menu first category News Views & Analysis Deep Dive Equity and Sustainability Research & Development Market Access Oncology Artificial Intelligence Patients & Partnerships GLP-1 Previous Editions Webinars Podcasts Videos Spotlight on ASCO BIO-Europe C-Suite Innovators ESMO Frontiers Health JP Morgan Global Policy Insights Events close SECTION News Views & Analysis Deep Dive Research & Develo … odegenerative disorder. GSK is paying out €33.5 million in cash to get the ball rolling, with another €140 million per target in potential milestones, according to a press statement, which notes that the programme will focus on using Muna's MiND-MAP platform to map the brain's response to the aggregation of proteins like amyloid and tau that is seen in Alzheimer's. The two companies will look at "cellular mechanisms, gene networks, and molecular interactions that underlie bra
Muna’s MTX-46943 sheds light on Alzheimer's therapy | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 landscape PFA r
Manuela Polydoro, Muna's Head of Translational Medicine, will be presenting a platform talk on our TREM2 small molecule agonist, which is progressing to Phase 1, at AAIC on Monday, July 28th.… | Rita Balice-Gordon LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices
Muna Therapeutics gets $4.9M grant for Parkinson’s research Skip to content Search for: Suggested Topics: Categories Browse by resource or article category Knowledge hub Resources Biotech funding tracker Biotech deals tracker Biotech layoff tracker Biotech events 2026 List of biotech grants Biotech associations Categories News and Trends In-depth Best in Biotech Podcasts Top Pharma Strategy Opinion Expert Advice Sponsored Mending university and venture capital relations: is it possible to see eye-to-eye? Portugal: will the life science sector see upswing amid funding worries? Sectors Browse by … rtise with us Podcast Reports Home News and Trends Muna Therapeutics gets $4.9M grant for Parkinson’s disease research Muna Therapeutics gets $4.9M grant for Parkinson’s disease research By Jim Cornall 3 minutes mins October 11, 2022 3 minutes mins Share WhatsApp Twitter Linkedin Email Photo/Shutterstock Newsletter Signup - Under Article / In Page " * " indicates required fields URL This field is for validation purposes and should be left unchanged. Subscribe to our … Job title * Business email * Muna Therapeutics has been awarded a $4.9 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). The grant will be used to support ongoing preclinical research and development of novel, brain-exposed, small molecule potassium channel type 1.3 (Kv1.3) blockers to abrogate neuroinflammation driven by disease-associated microglia and enhance neuroprotection as a disease-modifying therapy for patients with Parkinson’s disea … eased to receive this significant funding from The Michael J. Fox Foundation to fund this promising research which has the potential to significantly improve the lives of people with Parkinson’s. Kv1.3 plays an important role in creating and maintaining neuroinflammation in Parkinson’s and other neurodegenerative diseases. Reducing neuroinflammation by blocking Kv1.3 has tremendous potential to slow or prevent neurodegeneration and disease progression,” said Rita Balice-Gordo … ple with Parkinson’s,” said Brian Fiske, co-chief scientific officer, MJFF. The grant from MJFF will support work at Muna Therapeutics and in collaboration with Bart De Strooper at VIB/KU Leuven, a scientific co-founder of Muna, for two years. Neurological diseases R&D trends and breakthrough innovations Find out which indications have the fu
About Us | Muna Therapeutics About Us Our Team Board of Directors Our Scientific Founders Scientific Advisory Board Medicinal Chemistry Advisory Board Our Investors Our Science Careers News Contact About Muna Therapeutics Our Focus Muna Therapeutics discovers and develops therapies that slow or stop devastating neurodegenerative diseases including Alzheimer’s and Parkinson’s. These disorders impact memory, movement, language, behavior and personality, resulting in disability and death of millions of patients around the globe. We focus our groundbreaking science on identifying new medicines to
News | Muna Therapeutics About Us Our Team Board of Directors Our Scientific Founders Scientific Advisory Board Medicinal Chemistry Advisory Board Our Investors Our Science Careers News Contact News June 4, 2026 Muna Therapeutics Announces Nature Medicine Publication Validating Microglial State Transitions as Key Drivers of Alzheimer’s COPENHAGEN, Denmark and BOSTON, U.S., June 4, 2026 – Muna Therapeutics, a clinical-stage biotechnology company pioneering a new era of drug discovery for neurodegenerative diseases, today announced the publication of a seminal study in Nature Medicine: “Human mi … re January 8, 2026 Muna Therapeutics Awarded $1 Million Alzheimer's Association Grant to Advance Clinical Development of Novel Oral TREM2 Agonist MNA-001 for Alzheimer’s COPENHAGEN, Denmark and BOSTON, U.S., January 8, 2026 – Muna Therapeutics, a clinical-stage biotechnology company focused on developing innovative therapeutics for neurodegenerative diseases, today announced it has been awarded a $1 million research grant from the Alzheimer’s Association to support its ongoin
Muna Tuna – EY US Market Access Leader | EY - US EY Homepage Services Strategy by EY-Parthenon Strategy by EY-Parthenon Corporate & Growth Strategy Geopolitical Strategy Commercial Strategy Working Capital Turnaround & Restructuring Consulting Enterprise Reimaginedᵀᴹ Private Equity Value Creation Disruptive Strategy Economic Analysis About EY-Parthenon Transactions and Corporate Finance by EY-Parthenon Transactions and Corporate Finance by EY-Parthenon M&A Advisory M&A Integration M&A AI-powered Technology Divestment Strategy Corporate Finance Valuation, Modeling & Econ … ging Personalized professional growth How to join us Frequently asked questions Application and interview information Job search Early career opportunities MBA and advanced degree opportunities Experienced Contract Careers in EY-Parthenon Services</h3>\r\n"}}" id="rich-text-bdb7ae91ea2a" data-up-is="rich-text" data-up-translation-read-more="Read more" data-up-translation-read-less="Read less" data-up-translation-aria-label-read-more="Read more button, press enter to ac … trategy and Transactions How Bristol Myers Squibb overhauled working capital to fund its future 20 Aug 2025 Gerado Gonzalez Alliances How St James’s Hospital's journey to cloud transformed cancer care 09 Jun 2025 EY Americas Insights</h3>\r\n"}}" id="rich-text-1a0f7404a8e1" data-up-is="rich-text" data-up-translation-read-more="Read more" data-up-translation-read-less="Read less" data-up-translation-aria-label-read-more="Read more button, press enter to activate, or … stera Labs, were named the EY World Entrepreneur Of The Year 2026 winners at an award ceremony held in Monaco’s Salle des Etoiles. 29 May 2026 Entrepreneurship How AI drove Daikin’s business transformation from complexity to agility Daikin defined a North Star to align operations, empower people and guide sustainable global business transformation. 08 May 2026 Alliances My EY My EY Select your location Local sites Muna Tuna EY US Market Access Leader, Ernst & Young LLP Ad
Top 30 Copenhagen Startups to Watch in 2025 | GrowthMentor logo image Platform Back Platform Overview AI Matching Slack Community Help Requests Community Networking Video Room Explore all features See how GrowthMentor works Platform Overview Use Cases Back By Role Founders Marketers Product Managers Teams Venture Capital By Challenge Product Market Fit Raising Funding Growth Strategy Scaling Operations Sales Strategy Product Roadmapping Go to Market Strategy Personal Upskilling Team Building Getting First Customers Self-guided tour See the GrowthMentor platform in action in a brief product ove … iotechnology, Medical, Pharmaceutical Funding Amount $77,900,000 Funding Status Grant Employees 11-50 View Website FluoGuide FluoGuide maximizes surgical outcomes through intelligent targeting, reducing patient suffering and healthcare costs. Key Info When was it founded? 2018 Company Headquarters Copenhagen Founders Andreas Kjaer Industries Biotechnology, Health Care Funding Amount $28,685,576 Funding Status Post-IPO Equity Employees 11-50 View Website LinkedIn Twitter Orbis … ries Energy Storage, Renewable Energy Funding Amount $26,582,564 Funding Status Grant Employees 11-50 View Website LinkedIn EvodiaBio EvodiaBio, based in Copenhagen, creates natural and sustainable scents for the food and beverage industries. Key Info When was it founded? 2021 Company Headquarters Copenhagen Founders Victor Forman Industries Biotechnology Funding Amount $13,602,656 Funding Status Series A Employees 11-50 View Website LinkedIn Go Autonomous Go Autonomous simpl
#neuroscience #neurodegenerative #muna_tx #biotech #munatx | Rita Balice-Gordon LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User A
Holly Caplan - The latest episode of my podcast, Talking... Facebook Log In Holly Caplan's Post Holly Caplan December 13, 2022 · Shared with Public The latest episode of my podcast, Talking Confidence with Holly Caplan, is live now! Season 2, Episode 6, is with Rita Balice-Gordon, CEO of Muna Therapeutics! You can listen here: https://podcasts.apple.com/.../talking.../id1599763942... or you can find it wherever you get your podcasts! ---------------------------------------------------------------- Talking Confidence: Why Women Need Mentors How important is mentorship? I think it is very i
#trem2 #alzheimers | Muna Therapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and Cookie Po … or region This educational programme is supported by an Independent Educational Grant from Boehringer Ingelheim #MedicalEducation #Oncology #NETCancerDay #WorldNeuroendocrineCancerDay …more 51 3 Comments Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in EDM Medical Solutions 4,340 followers 7mo Edited Report this post Toughest-to-treat cancers don’t just test the body. They test life after treatment. Dr. Natasha Sheybani ，Assistant Professor of Bio
Episode 89 - Rita Balice-Gordo…–The BioHub - by Avetix – Apple Podcasts Search Home New Top Charts Search 12 November 2025 25 min Episode 89 - Rita Balice-Gordon - Muna Therapeutics The BioHub - by Avetix Play Rita is the CEO of Muna Therapeutics, a biotech company focused on discovering and developing therapies that restore the function of diseased neurons and slow or stop neurodegeneration. In this conversation, we explore Rita’s career journey and what inspired their move into biotech leadership, as well as what first drew them to Muna Therapeutics. We talk about Muna’s scientific focus, ho
Episode 89 - Rita Balice-Gordon - Muna Therapeutics - The BioHub - by Avetix | Podcast on Spotify
Microglia transitions act as critical turning point in Alzheimer's Skip to content Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life Sciences Home About Functional Food News Health A-Z Drugs Medical Devices Interviews White Papers More... MediKnowledge eBooks Posters Podcasts Videos Newsletters Health & Personal Care Contact Meet the Team Advertise Search Become a Member Top Health Categories Coronavirus Disease COVID-19 Diet & Nutrition Artificial Intelligence Allergies Alzheimer's & Dementia Arthritis & Rheumatology Breast Cancer Breastfeeding … nfidential information. Read the full Terms & Conditions . Provide Feedback Submit Cancel You might also like... × U-M Health neurosurgeons complete first human implant of wireless brain computer interface
#alzheimers #brainresilienceapproach | Muna Therapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Poli
Muna AD/PD 2026 Presentations | Muna Therapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , an … ter Charitable Foundation 3,608 followers 3mo Report this post A 2026 Rainwater Prize winner and Mayo Clinic neuroscientist, Dr. Melissa E. Murray ‘s work integrates neuropathology, neuroimaging, and biomarkers to distinguish between biologically distinct tauopathies, a critical insight for diseases where tau is the primary driver. 🎧 Listen to this episode of the Alzheimer’s Breakthrough podcast as Dr. Murray explains how earlier, more precise detection and brain donation ar
Microglial State Shift May Determine Whether Alzheimer’s Disease Pathology Leads to Dementia | Inside Precision Medicine clinicalomicsprowebdirectory Facebook Linkedin Twitter News Topics Informatics Molecular Dx Patient Care Oncology Precision Medicine Translational Research Magazine Browse Issues Subscribe Subscribe Get Inside Precision Medicine Magazine Get Inside Precision Medicine eNewsletters Multimedia Webinars Summits Podcasts Videos Inside Precision Medicine Live Learning Labs eBooks Search Facebook Linkedin Twitter Sign in Welcome! Log into your account your username your password Fo
Muna Therapeutics Launches with US$ 73M Series A to Advance Novel Small Molecule Therapeutics for Neurodegenerative Diseases Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia G … ng co-led by Novo Holdings, Sofinnova Partners, Droia Ventures and LSP Dementia Fund, with participation from Polaris Partners, Polaris Innovation Fund, Sanofi Ventures, V-Bio Ventures and VIB - Developing small molecules to repair neuronal dysfunction and resolve neuroinflammation - Innovative drug discovery platform leveraging insights from novel targets and pathways, resilience to neurodegeneration and all-in-human validation News provided by Muna Jul 09, 2021, 00:00 ET Sh … as co-led by Novo Holdings, Sofinnova Partners, Droia Ventures and LSP Dementia Fund, with Polaris Partners, Polaris Innovation Fund, Sanofi Ventures, V-Bio Ventures and VIB joining the round. Muna is the combination of two innovative European start-up companies. Muna was founded in 2020 by progranulin pathway thought leaders Professor Simon Glerup and his team from Aarhus University, Denmark , with investor Novo Holdings. Muna developed a strategic partnership on additional … to co-lead this round with Sofinnova Partners, Droia Ventures and LSP Dementia Fund – a tremendous joint effort to bring Muna to the next level." About Muna Therapeutics Muna Therapeutics is a private biopharmaceutical company founded in 2020 and based in Copenhagen, Denmark and Leuven, Belgium . Muna discovers and develops therapies that slow or stop devastating neurodegenerative diseases including Alzheimer's, Frontotemporal Dementia and Parkinson's. These dis … a invests globally in newly founded or early-stage platform companies that apply novel science and innovative technologies to bring first-in-class drug candidates to patients. With our team of seasoned scientists, entrepreneurs and investment professionals we build great companies to save patient lives. w
Muna doses first subjects in MNA-001 study to treat early Alzheimer’s Skip to site menu Skip to page content Switch language: .translate --> CT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Approvals Operations Outsourced Services Supply Chain Data Management Medical Devices Themes Artificial Intelligence Cloud Corporate Governance Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insights Deals Jobs Filings Patents Social Media Companies Company A-Z Company Categories Produc … Chain Data Management Medical Devices Latest Ollin Biosciences secures $330m to fund Phase III OLN324 trials Viking Therapeutics commences Phase I trial of VK3019 Ascletis receives FDA clearance for Phase I trial of obesity treatment Themes Sections Artificial Intelligence Cloud Corporate Governance Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Foreign Direct Investment Latest How wearables can unlock their full potentia
MUNA — Film Festival Distribution 0 Skip to Content Catalogue What we do Contact Open Menu Close Menu Catalogue What we do Contact Open Menu Close Menu Catalogue What we do Contact Connecting independent cinema and film festivals worldwide MUNA is a film agency focused on marketing and festival circulation for shorts and features, regardless of genre or country of origin. We offer carefully crafted distribution strategies tailored to each film in order to bring it closer to audiences all across the world. Find out more
%PDF-1.3 %��������� 3 0 obj > stream x����ܸ���ϧH�*�K���$3yI�}�۷VOO�g4�x�z/��� {w��}�y��~8$Pj2���(&A88w ����~�o�ǯ�Vm�۶� ��ۏ �9܅ ��t9���T ��Ro���o�s C���������>����n���,����o���#�A �u��r M�ѵ���/��Y���8 w�o�S �����H�?R ��� 0� O��6�&d ����П�Y��:�u ���/6�ެ�\)e���pBr j�b�ڈ�O��pjgxd�FL�'�61�թ9 �& ���z�*F�x�l��FM#`g7����b5v�bV�=��V|�:��?�%���0It ��d�ͩ=�(�S�\�I�8����D�~� 0�ErDuN.�V&��|d�q ��@[.��� �ߧ�?OoL��x&Z#U��ڗ"�.�$1 b��1�3)�f1u G�����hTY���6{� E���Z�͞���Fx�����Žl�= �}uI�=] 胔5�\?:Cr5�� ��� �XLh��R��#H�l{ݟ�AG�o/6[�; d�Ms諶�iW����9�� 2�����q\.�y�L!@�9��C
Muna Therapeutics Announces First Subjects Dosed in Phase 1 Trial of Novel Oral TREM2 Agonist for Early Alzheimer's Disease - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Muna Therapeutics Announces First Subjects Dosed in Phase 1 Trial of Novel Oral TREM2 Agonist for Early Alzheimer’s Disease November 10, 2025 | 3 min read Twitter LinkedIn Facebook Email Print MNA-001 has best-in-class potential based on preclinical data demonstrating ability to significantly reduce … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Muna Therapeutics Announces Strategic Alliance with GSK to Accelerate Development of Novel Treatments for Alzheimer's Disease - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deal … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Muna Therapeutics Announces Strategic Alliance with GSK to Accelerate Development of Novel Treatments for Alzheimer’s Disease December 6, 2024 | 3 min read Twitter LinkedIn Facebook Email Print Multi-year effort leverages Muna's all-in-human MiND-MAP spatial multi-omics approach to identify and validate n … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Muna Therapeutics Awarded $1 Million Alzheimer's Association Grant to Advance Clinical Development of Novel Oral TREM2 Agonist MNA-001 for Alzheimer's - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Deve … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Muna Therapeutics Awarded $1 Million Alzheimer’s Association Grant to Advance Clinical Development of Novel Oral TREM2 Agonist MNA-001 for Alzheimer’s January 9, 2026 | 3 min read Twitter LinkedIn Facebook Email Print Funds to support ongoing Phase 1 trial of MNA-001 and validation of translational biomar … egenerative diseases, today announced it has been awarded a $1 million research grant from the Alzheimer's Association to support its ongoing Phase 1 trial of MNA-001 —a novel potent, selective and orally administered small molecule, in healthy young and elderly subjects—and its work to identify and validate translational biomarkers of the function and activation of triggering receptor expressed on myeloid cells 2 (TREM2) in the context of Alzheimer's disease. These efforts w … ing neuroinflammation. "We are grateful to the Alzheimer's Association for this award, which will accelerate clinical evaluation of MNA-001 and validation of critical biomarkers of TREM2 agonism," said Rita Balice-Gordon, Ph.D., Chief Executive Officer of Muna Therapeutics. "The grant supports our strategy to shift the treatment paradigm from clearing pathology to bolstering the brain's innate protective mechanisms. By recalibrating microglial activity, we aim to interrupt th … vide a potentially transformative approach to treating early Alzheimer's." This award underscores Muna's growing momentum and its leadership in the discovery of resilience-based therapeutics to slow or stop devastating diseases like Alzheimer's to improve the quality of life for patients and their loved ones. About Muna Therapeutics Muna Therapeu
BioSpace Movers & Shakers, Nov. 5 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Rel … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business BioSpace Movers & Shakers, Nov. 5 November 4, 2021 | 7 min read | Alex Keown Twitter LinkedIn Facebook Email Print Biopharma and life sciences organizations strengthen their leadership teams and board with these Movers & Shakers. Biopharma and life sciences organizations … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Muna Therapeutics Announces Nature Medicine Publication Validating Microglial State Transitions as Key Drivers of Alzheimer's - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deal … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Muna Therapeutics Announces Nature Medicine Publication Validating Microglial State Transitions as Key Drivers of Alzheimer’s June 4, 2026 | 3 min read Twitter LinkedIn Facebook Email Print Study leveraging Muna's MiND-MAP platform identifies critical tipping point in microglial response to amyloid and ta … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Muna Therapeutics Raises $73 Million to Advance Neurodegenerative Disease Focus - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Muna Therapeutics Raises $73 Million to Advance Neurodegenerative Disease Focus July 9, 2021 | 2 min read | Brandon May Twitter LinkedIn Facebook Email Print The company launches with the new funding to advance its focus on first-in-class small molecule therapies for neurodegener … oldings in conjunction with Sofinnova Partners, DROIA Ventures and LSP Dementia Fund. Additional investors who joined the financing round included Polaris Partners, Polaris Innovation Fund, Sanofi Ventures, V-Bio Ventures and VIB. Muna’s primary focus—neurodegenerative diseases—lead to disability and death of millions of people worldwide. There are currently no curative therapies available for many neurodegenerative conditions, a problem Muna hopes to address. The company was … to co-lead this round with Sofinnova Partners, Droia Ventures and LSP Dementia Fund—a tremendous joint effort to bring Muna to the next level.” Muna also collaborated with K5 Therapeutics, a company cofounded last year by Professor Bart De Strooper from VIB-KU Leuven in Belgium, in addition to investors VIB and Droia Ventures. As such, the combined company Muna Therapeutics will be based in both Copenhagen, Denmark, and Leuven, Belgium. Leaders of the company include Chief E … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
BioSpace - The Muna partnership will give GSK access to... Facebook Log In BioSpace's Post BioSpace December 5, 2024 · Shared with Public The Muna partnership will give GSK access to Muna’s MiND-MAP platform, which it will apply to postmortem brain samples to identify potential therapeutic targets for Alzheimer’s disease. #alzheimers #pharma #biospace biospace.com GSK Strikes Third Agreement This Week, Leans Further Into Neuro Like Comment
Muna Therapeutics ApS Aarhus University logo For students For PhDs For employees Departments and faculties AU Library Brightspace MYSTUDIES.AU.DK Common pages for PhD students phd.au.dk PhD-portals Employee portals Find the local staff portal for your department or division. Departments and faculties Education International admissions at AU Bachelor's degree programmes Master's degree programmes Exchange programmes AU Summer University PhD programmes Meet AU Ask about studies Chat with our students International student blog Fairs and events On-demand webinars AU in many languages How … al student blog Fairs and events On-demand webinars AU in many languages How to apply Bachelor’s degree programmes Master’s degree programmes Exchange programmes Summer University PhD programmes Education Research Research units and facilities Departments and schools Research centres Research facilities Research support Find a researcher PhD studies PhD at AU PhD programmes Vacant PhD positions How to apply Career services Researcher positions Vacant positions Fellowship prog … ant positions Fellowship programme at AIAS Attractive working conditions How to apply Funding opportunities Junior Researcher services Junior Researcher Association Campus resources Career services Research Life in Denmark Danish way of living Cost of living Family and work-life balance The Danes Learning and teaching culture Your new city Aarhus and surroundings Things to do in Aarhus Getting around AU locations For students Prepare your arrival Student housing Student life
Muna Therapeutics ApS - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 08 May 2025 Muna Therapeutics ApS Startups | Holding Company | 2020 | Denmark | 10-50 | munatherapeutics.com Startups | Holding Company | 2020 | Denmark | 10-50 | munatherapeutics.com Last update 08 May 2025 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Nervous System Diseases Immune System Diseases Endocrinology and Metabolic Disease Small molecule drug Disease domain score A glimpse … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
Muna Therapeutics Announces Strategic Alliance with GSK to Accelerate Development of Novel Treatments for Alzheimer's Disease Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia … y announced the... Muna Therapeutics Awarded $1 Million Alzheimer's Association Grant to Advance Clinical Development of Novel Oral TREM2 Agonist MNA-001 for Alzheimer's Muna Therapeutics, a clinical-stage biotechnology company focused on developing innovative therapeutics for neurodegenerative diseases, today... More Releases From This Source Explore Health Care & Hospitals Medical Pharmaceuticals Biotechnology Pharmaceuticals News Releases in Similar Topics --> Contact … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Muna Therapeutics — Sofinnova Partners Submit a project Submit a project Submit a project Contact Us Privacy Policy Regulatory Information Legal Terms ESG About Strategies Team Portfolio News 0 results Muna Therapeutics Muna is the combination of two innovative European start-up companies. Muna was founded in 2020 by progranulin pathway thought leaders Professor Simon Glerup and his team from Aarhus University, Denmark, with investor Novo Holdings. Muna developed a strategic partnership on additional targets with Axxam SpA, based in Milan, Italy, which became a minority shareholder. Muna is pa … tments for Alzheimer’s Disease 11 October, 2022 Muna Therapeutics awarded $4.9M grant from The Michael J. Fox Foundation for Parkinson's research 9 July, 2021 Muna Therapeutics raises $73M Series A for neurodegeneration Sofinnova Capital The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies. Sofinnova MD Start The Sofinnova MD Start Stra
Team Page About Us Our Team Board of Directors Our Scientific Founders Scientific Advisory Board Medicinal Chemistry Advisory Board Our Investors Our Science Careers News Contact Our Team Our team has years of neurology drug discovery and development experience in the pharmaceutical and biotechnology arenas and is supported by world-class scientific founders and advisors. Rita Balice-Gordon, PhD Chief Executive Officer Rita brings 30 years of experience in neuroscience research, drug discovery and development from senior leadership roles in biopharma and a distinguished academic research caree
XBRL Viewer Please enable JavaScript to use the EDGAR Inline XBRL Viewer.
Muna Therapeutics Launches with US$ 73M Series A to Advance About Novo Group Leadership Responsibility Novo Nordisk Foundation About Investments Areas Life Science Seed Investments Venture Investments Principal Investments Planetary Health Investments Capital Investments Strategy Regions North America Europe Asia Portfolio Investments People Careers Open positions People & Careers News & Reports Facts & Figures Media Library Contact Public Relations News & Reports News July 9, 2021 Muna Therapeutics Launches with US$ 73M Series A to Advance Novel Small Molecule Therapeutics for … ng co-led by Novo Holdings, Sofinnova Partners, Droia Ventures and LSP Dementia Fund, with participation from Polaris Partners, Polaris Innovation Fund, Sanofi Ventures, V-Bio Ventures and VIB Developing small molecules to repair neuronal dysfunction and resolve neuroinflammation Innovative drug discovery platform leveraging insights from novel targets and pathways, resilience to neurodegeneration and all-in-human validation Copenhagen, Denmark, 9th July 2021 – Muna Therapeut … as co-led by Novo Holdings, Sofinnova Partners, Droia Ventures and LSP Dementia Fund, with Polaris Partners, Polaris Innovation Fund, Sanofi Ventures, V-Bio Ventures and VIB joining the round. Muna is the combination of two innovative European start-up companies. Muna was founded in 2020 by progranulin pathway thought leaders Professor Simon Glerup and his team from Aarhus University, Denmark, with investor Novo Holdings. Muna developed a strategic partnership on additional t … to co-lead this round with Sofinnova Partners, Droia Ventures and LSP Dementia Fund – a tremendous joint effort to bring Muna to the next level.” About Muna Therapeutics Muna Therapeutics is a private biopharmaceutical company founded in 2020 and based in Copenhagen, Denmark and Leuven, Belgium. Muna discovers and develops therapies that slow or stop devastating neurodegenerative diseases including Alzheimer’s, Frontotemporal Dementia and Parkinson’s. These disorders impact … Droia invests globally in newly founded or early-stage platform companies that apply novel science and innovative technologies to bring first-in-class drug candidates to patients. With our team of seasoned scientists, entrepreneurs and investment professionals we build great companies to save patient lives. www.droiaventures.com . About LSP LSP
News Details About Us Our Team Board of Directors Our Scientific Founders Scientific Advisory Board Medicinal Chemistry Advisory Board Our Investors Our Science Careers News Contact July 9, 2021 Muna Therapeutics Launches with US$ 73M Series A to Advance Novel Small Molecule Therapeutics for Neurodegenerative Diseases Financing co-led by Novo Holdings, Sofinnova Partners, Droia Ventures and LSP Dementia Fund, with participation from Polaris Partners, Polaris Innovation Fund, Sanofi Ventures, V-Bio Ventures and VIB Developing small molecules to repair neuronal dysfunction and resolve neuroinfla … as co-led by Novo Holdings, Sofinnova Partners, Droia Ventures and LSP Dementia Fund, with Polaris Partners, Polaris Innovation Fund, Sanofi Ventures, V-Bio Ventures and VIB joining the round. Muna is the combination of two innovative European start-up companies. Muna was founded in 2020 by progranulin pathway thought leaders Professor Simon Glerup and his team from Aarhus University, Denmark, with investor Novo Holdings. Muna developed a strategic partnership on additional t … to co-lead this round with Sofinnova Partners, Droia Ventures and LSP Dementia Fund – a tremendous joint effort to bring Muna to the next level.” ENDS For more information please contact: Muna Therapeutics Rita Balice-Gordon, CEO Email: [email protected] Optimum Strategic Communications Mary Clark, Manel Mateus, Stella Lempidaki Tel: +44 (0) 20 3922 1906 Email: [email protected] About Muna Therapeutics Muna Therapeutics is a private biopharmaceutical comp … Droia invests globally in newly founded or early-stage platform companies that apply novel science and innovative technologies to bring first-in-class drug candidates to patients. With our team of seasoned scientists, entrepreneurs and investment professionals we build great companies to save patient lives. www.droiaventures.com About LSP LSP is one of the largest European investment firms providing financing for life sciences and health care companies. LSP’s management has … 2 focuses on private late-stage medical technology companies; the LSP Dementia Fund invests in companies targeting neurodegenerative diseases; LSP Public targets public healthcare companies; and EBAC is the first healthcare SPAC to exclusively focus on European biotech. LSP is an active contributor to the global life sciences industry and the Eu
Language profile of five IDP sites in Maiduguri: Muna Host Community - Translators without Borders Translators without Borders Email Facebook Instagram LinkedIn Twitter Donate Now About us Careers Testimonials Our work Crisis Response European refugee response Global COVID-19 response Mozambique Northeast Nigeria Rohingya response The Democratic Republic of Congo Gamayun Language Initiative Language Data Initiative TWB Platform TWB Chatbots TWB Glossaries Resources Support us Donate to Translators without Borders Become a Fundraiser Corporate Sponsorships Give financial support Give pro bono s … olunteer role Community Recognition Program Partner with us TWB Partner Program Apply to be a Partner News & Blog Blog Press Donate Now Language profile of five IDP sites in Maiduguri: Muna Host Community October 21, 2021 by This site report for Muna Host summarizes the key findings from a comprehension study designed by Translators without Borders and conducted by Girl Effect using Oxfam communication materials among 951 internally displaced people (IDPs) and host commu … olunteer role Community Recognition Program Partner with us TWB Partner Program Apply to be a Partner News & Blog Blog Press Donate Now About us Careers Testimonials Our work Crisis Response European refugee response Global COVID-19 response Mozambique Northeast Nigeria Rohingya response The Democratic Republic of Congo Gamayun Language Initiative Language Data Initiative TWB Platform TWB Chatbots TWB Glossaries Resources Support us Donate to Translators without Borders … olunteer role Community Recognition Program Partner with us TWB Partner Program Apply to be a Partner News & Blog Blog Press Donate Now
PIR International Interview with Rita Balice-Gordon, CEO, Muna Therapeutics | BIA Skip to content Influencing policy Business environment Finance and tax IP and tech transfer Regulation Skills and talent Manufacturing Medicines Access to medicines Cell and gene therapy Antimicrobial Resistance Use of animals in research Critical technologies Biosolutions Engineering Biology TechBio Genomics mRNA Growing the sector Skills, talent and people Sector jobs Resources Future talent Diversity and inclusion Invest in biotech Women in Biotech Developing your company Protecting your company BioStart: for … our company BioStart: for early-stage entrepreneurs Search sector opportunities Submit a sector opportunity Innovation Map Become a member BIA Membership directory Member benefits Your guide to navigating the BIA website Join BIA member community Save with Business Solutions Join BIA Interested in membership? Enquire about joining BIA News and insights Resources Member news Submit member news Press releases Media centre Sign up to Newscast Blogs Blog guidelines Reports BIA in … lines Reports BIA international Events BIA Events BioSolutions UK Sector events Submit sector events London Life Sciences Week Supporting BIA events Event FAQs About What is biotech? Meet the team Our board Articles of Association Charity partnership Our charity partnerships Careers Our supporters Login/Register Join BIA You are here: BioIndustry Association News and insights Resources PIR International Interview with Rita Balice-Gordon, CEO, Muna Therapeutics Member news 15 … mark. My only regret is not doing it a decade earlier! Realisation that you can apply science expertise to a real-world impact for patients. Who has had the greatest influence over your career? Middle school science teacher. So generous with time. High school college teachers. Great advice for aspiring academic. PhD advisor, Wesley Thomson. Showed me I could do science with high integrity and have a lot of fun doing it. Always gave good advice even if I didn’t want to h … on and listening skills to work this out. Don’t preconceive and impose or apply one size fits all attitude. Are there particular leadership characteristics which have encouraged greater cultural diversity in your company, resulting in different behaviours and outcomes? Humility above all; and a team focused leader. Understand you can’
PharmiWeb.com – Thank you 1998 – 2026 AFTER TWENTY–EIGHT YEARS Thank you. Thank you for building PharmiWeb.com Since 1998, this community has helped people find opportunities, build careers, and connect across the industry. As we close this chapter, we do so with gratitude and pride in what we created together. For everyone who found an opportunity here, from entry-level roles to VP positions , and everything in between. And for every advertiser, partner, reader, and every member of the PharmiWeb team since 1998. We were there at the beginning of the dot-com era, even beating
News Details About Us Our Team Board of Directors Our Scientific Founders Scientific Advisory Board Medicinal Chemistry Advisory Board Our Investors Our Science Careers News Contact December 5, 2024 Muna Therapeutics Announces Strategic Alliance with GSK to Accelerate Development of Novel Treatments for Alzheimer’s Disease Multi-year effort leverages Muna's all-in-human MiND-MAP spatial multi-omics approach to identify and validate new drug targets and treatment pathways for Alzheimer’s disease GSK secures option to multiple high-value, validated Alzheimer’s-relevant targets for drug disc